Cinclus Pharma Holding AB (publ) Feed

Land	Sverige
Lista	Mid Cap Stockholm
Sektor	Hälsovård
Industri	Bioteknik

2024-07-19 18:30:00 Notice of stabilization, end of stabilization period and that the over-allotment option has not been exercised

2024-07-19 18:30:00 Meddelande om stabiliseringsåtgärder, avslutande av stabiliseringsperioden och att övertilldelningsoptionen inte har utnyttjats

2024-07-11 19:00:00 Stabilization notice 0,00% | 7,11 MSEK

2024-07-11 19:00:00 Meddelande om stabiliseringsåtgärder 0,00% | 7,11 MSEK

2024-07-01 18:30:00 Stabilization notice +8,57% | 29,4 MSEK

2024-07-01 18:30:00 Meddelande om stabiliseringsåtgärder +8,57% | 29,4 MSEK

2024-06-28 08:45:00 Number of shares and votes in Cinclus Pharma +1,64% | 16,7 MSEK

2024-06-28 08:45:00 Antal aktier och röster i Cinclus Pharma +1,64% | 16,7 MSEK

2024-06-20 07:30:00 First day of trading in Cinclus Pharma’s ordinary shares on Nasdaq Stockholm -22,37% | 179 MSEK

2024-06-20 07:30:00 Första dag för handel i Cinclus Pharmas stamaktier på Nasdaq Stockholm -22,37% | 179 MSEK

2024-06-10 09:05:00 Cinclus Pharma announces listing on Nasdaq Stockholm and offering of ordinary shares as well as publishes related prospectus

2024-06-10 09:05:00 Cinclus Pharma offentliggör notering på Nasdaq Stockholm och erbjudande av stamaktier samt publicerar tillhörande prospekt

2023-11-23 08:00:00 Cinclus Pharma meddelar positivt FDA-besked

2023-11-23 08:00:00 Cinclus Pharma announces positive FDA interaction

2023-10-16 08:00:00 Cinclus Pharmas fas II eGERD-studie i två presentationer vid UEG

2023-10-16 08:00:00 Cinclus Pharma's phase II eGERD study in two presentations at UEG

2023-05-09 08:00:00 Cinclus Pharma’s phase II eGERD study in oral presentation at DDW

2023-05-09 08:00:00 Cinclus Pharmas fas II eGERD-studie i muntlig presentation vid DDW

2022-11-04 08:00:00 Cinclus Pharma announces positive topline results from the LEED phase II eGERD study

2022-11-04 08:00:00 Cinclus Pharma meddelar positiva topline-resultat från fas II eGERD-studien LEED

2022-09-05 08:00:00 Cinclus Pharma erhåller beviljande av QIDP

2022-09-05 08:00:00 Cinclus Pharma receives QIDP designation

2022-07-01 15:00:00 Cinclus Pharma includes the last patient in its phase II eGERD study

2022-07-01 15:00:00 Cinclus Pharma inkluderar sista patienten i sin fas II-eGERD-studie

2022-05-20 08:00:00 Cinclus Pharma has carried out a successful private placement of approximately SEK 240 million

2022-03-02 08:00:00 Cinclus Pharma appoints Kajsa Larsson as Chief Medical Officer

2021-11-29 08:00:00 Cinclus Pharma Appoints Gösta Hiller as Chief Operating Officer

2021-09-06 14:00:00 Cinclus Pharma receives approval of the International Nonproprietary Name (INN) linaprazan glurate for its lead drug candidate for the treatment of GERD

2021-08-27 08:00:00 Cinclus Pharma Appoints Maria Engström as Chief Financial Officer

2021-08-18 11:00:00 Cinclus Pharma announces the first patient randomized in the Phase II study for X842 in GERD.

2021-02-25 08:30:00 Cinclus Pharma utser Christer Ahlberg till VD

2021-02-25 08:30:00 Cinclus Pharma Appoints Christer Ahlberg as Chief Executive Officer

2020-04-16 09:00:00 Cinclus Pharma utser Jenni Björnulfson till Chief Financial Officer

2020-03-04 08:30:00 Cinclus Pharma säkrar SEK 250 miljoner för den fortsatta utvecklingen av ett nytt läkemedel mot gastroesofagal refluxsjukdom

2019-04-24 10:40:00 Cinclus Pharma announces news on the further development of X842 and secures financing thru a directed share issue of SEK 28 million, to prepare initiation of clinical Phase 2 study

2018-10-15 08:00:00 Cinclus Pharma abstract selected Poster of Excellence at the UEGW conference

2018-04-16 10:30:00 First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2025-05-22	Årsstämma 2025
2025-05-20	Kvartalsrapport 2025-Q1
2025-02-20	Bokslutskommuniké 2024
2024-11-14	Kvartalsrapport 2024-Q3
2024-08-29	Kvartalsrapport 2024-Q2

Cinclus Pharma Holding AB (publ)

Prenumeration

Kalender

Beskrivning

Cinclus Pharma Holding AB (publ)

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden